GASTROENTEROLOGY / HEPATOLOGY
Goals: The division will continue to grow a world-renowned faculty group and further diversify recruitments for the best and brightest GI and Liver faculty nationwide; increase extramural funding through federal and federal passthrough sources contributing to the school’s increased rank in US News & World Report; continue to be one of the most sought-after programs by incoming fellows, and grow the fellowship programs through innovative curriculum that will prepare graduating fellows for clinical excellence & leadership across the country.
Clinical Areas of Excellence:
pancreaticobiliary disease and advanced endoscopy (including ERCP, EUS & Advanced luminal); motility and gastroenterology; inflammatory bowel disease; colorectal cancer; liver disease
Education Areas of Excellence:
inpatient and outpatient settings, covering the various aspects of general gastroenterology, inflammatory bowel disease, motility disorders, pancreatobiliary diseases and liver diseases; fellows experience a minimum of 5 dedicated months to research and gain a large experience in managing transplant patients, including liver transplant and multivisceral transplant, and their endoscopy experience exceeds national requirements both in quantity and nature of procedures
Research Areas of Excellence:
pancreatobiliary disease; device and new endoscopic procedures; motility/neurogastroenterology; inflammatory bowel disease; colorectal cancer; obesity and nutrition; fatty liver disease; alcoholic liver disease; drug induced liver injury; cholestatic liver disease; autoimmune hepatitis; cirrhosis complications and outcomes; liver transplantation; basic research in hepatology
LEADERSHIP & ADMINISTRATION
MOHAMMAD AL-HADDAD, MD
Professor of Medicine
Naga P. Chalasani Professor of Gastroenterology and Hepatology
Division Director
ROBERT SIWIEC, MD
Assistant Professor of Clinical Medicine
Interim Service Line Leader
CHELSIE WILLOUGHBY
Division Administrator
HOLLIE MAYES
Service Line Administrator
Christen Dilly, MD
Assistant Dean for Graduate Medical Education
Naga Chalasani, MD
Vice President of Academic Affairs for IU Health
Suthat Liangpunsakul, MD, MPH
Chair of P&T Committee
Lauren Nephew, MD
Associate Vice Chair for Health Equity, Department of Medicine
Ashley Gilmore, MD
Assistant Vice Chair for Health Equity, Department of Medicine
Charles Kahi, MD
Editor in Chief of Clinical Gastroenterology and Hepatology
Mohammad Al-Haddad, MD
Assoc. Editor of Clinical Gastroenterology and Hepatology
Suthat Liangpunsakul, MD, MPH
Associate Editor of Hepatology
Douglas Rex, MD
President of the American Society of Gastrointestinal Endoscopy (ASGE) (through May 2022)
KEY CLINICAL EDUCATORS
Christen Dilly, MD
Associate Professor of Medicine
Assistant Dean for Graduate Medical Education
Umer Bhatti, MD
Assistant Professor of Clinical Medicine
FEATURED FACULTY
THOMAS IMPERIALE, MD
Lawrence Lumeng Professor of Gastroenterology and Hepatology
- Named Distinguished Professor in March 2022
STUART SHERMAN, MD
Glen A. Lehman Professor of Gastroenterology
- Leads the flagship Advanced Endoscopy Program
- Selected to be the recipient of the American Society for Gastrointestinal Endoscopy’s Rudolf Schindler Award in 2023
NOTABLE PUBLICATIONS
Imperiale TF. Colorectal cancer screening offering colonoscopy and FIT vs. colonoscopy alone improved participation. Ann Intern Med. 2021 Jul;174(7):JC76. doi: 10.7326/ACPJ202107200-076. Epub 2021 Jul 6. PMID: 34224268.
Vuppalanchi R, Caldwell SH, Pyrsopoulos N, deLemos AS, Rossi S, Levy C, Goldberg DS, Mena EA, Sheikh A, Ravinuthala R, Shaikh F, Bainbridge JD, Parmar DV, Chalasani NP. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol. 2022 Jan;76(1):75-85. doi: 10.1016/j.jhep.2021.08.025. Epub 2021 Sep 4. PMID: 34487750.
Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-α/α Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19. PMID: 33811367
ASSOCIATED RESEARCH CENTERS
Indiana Center for Liver Research
Director: Gianfranco Alpini, PhD